Vishwas Seshadri Sells 50,676 Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) Stock

Abeona Therapeutics Inc (NASDAQ:ABEO - Get Free Report) CEO Vishwas Seshadri sold 50,676 shares of the business's stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $6.76, for a total value of $342,569.76. Following the transaction, the chief executive officer now owns 1,303,761 shares in the company, valued at approximately $8,813,424.36. This represents a 3.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Vishwas Seshadri also recently made the following trade(s):

• On Monday, March 31st, Vishwas Seshadri sold 25,000 shares of Abeona Therapeutics stock. The stock was sold at an average price of $4.78, for a total value of $119,500.00.

Abeona Therapeutics Stock Up 4.0%

Shares of ABEO stock traded up $0.26 during trading hours on Friday, reaching $6.74. The company had a trading volume of 938,085 shares, compared to its average volume of 639,223. The stock's fifty day simple moving average is $5.51 and its 200 day simple moving average is $5.57. Abeona Therapeutics Inc has a twelve month low of $3.93 and a twelve month high of $7.32. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. The company has a market capitalization of $344.80 million, a P/E ratio of -2.51 and a beta of 1.68.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last issued its earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.11. As a group, sell-side analysts expect that Abeona Therapeutics Inc will post -1.16 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Stifel Nicolaus decreased their price objective on shares of Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating for the company in a research report on Friday, May 16th. Alliance Global Partners reaffirmed a "buy" rating on shares of Abeona Therapeutics in a report on Thursday, May 15th. Wall Street Zen downgraded Abeona Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 15th. HC Wainwright boosted their price objective on shares of Abeona Therapeutics from $15.00 to $20.00 and gave the stock a "buy" rating in a report on Wednesday, April 30th. Finally, Oppenheimer began coverage on shares of Abeona Therapeutics in a research report on Monday. They issued an "outperform" rating and a $19.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $19.25.

Institutional Investors Weigh In On Abeona Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Wellington Management Group LLP acquired a new position in shares of Abeona Therapeutics during the fourth quarter valued at approximately $520,000. Jane Street Group LLC boosted its stake in Abeona Therapeutics by 894.8% during the 4th quarter. Jane Street Group LLC now owns 131,478 shares of the biopharmaceutical company's stock valued at $732,000 after purchasing an additional 118,262 shares in the last quarter. Trexquant Investment LP acquired a new position in shares of Abeona Therapeutics during the 4th quarter valued at $382,000. Northern Trust Corp raised its stake in shares of Abeona Therapeutics by 6.6% in the 4th quarter. Northern Trust Corp now owns 184,929 shares of the biopharmaceutical company's stock worth $1,030,000 after buying an additional 11,478 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp bought a new stake in shares of Abeona Therapeutics in the 4th quarter worth $362,000. Institutional investors and hedge funds own 80.56% of the company's stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.